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Graft-versus-host  responses  (GVHR) 1 occur  when  immunocompetent  lymphoid 
cells  are  transferred  from  a  donor  to  an  allogeneic  host  (1).  Donor  lymphocytes 
recognize alloantigens on host  cell membranes and  are stimulated  to proliferate.  If 
the host has a  reduced  immune competency (neonatal mouse or immunosuppressed 
recipient),  then  donor cells can  invade and  damage host  tissues  causing a  runting 
syndrome, termed graft-versus-host disease (GVHD). This condition is manifested by 
weight and hair loss and diarrhea. In severe cases, it results in death of the recipient. 
Clinically, GVHD frequently follows bone marrow transplantation  (2). 
The GVHR can be divided into a  proliferative phase and an effector phase which 
correspond  to  the  in  vitro  mixed  lymphocyte  reaction  (MLR)  and  cell-mediated 
lympholysis (CML) reaction, respectively (3). The proliferative phase of the GVHR 
can be quantitated  by measuring splenomegaly in a spleen weight assay (1), or by a 
lymph node weight assay (4). The effector phase of the GVHR (manifested as GVHD) 
may be quantitated by recording the survival time of the recipient and by observing 
the recipients for signs of GVHD (3). 
Previous studies of the GVHR have demonstrated that the main stimulus for the 
proliferative  phase  of  the  GVHR  is  provided  by  an  incompatibility  in  the  I-A 
subregion of the mouse H-2 major histocompatibility complex (MHC)  (3, 5-7). K- or 
D-region differences induce much weaker GVHR, whereas/-C-subregion differences 
require  the  preimmunization  of donors  to  produce  significant  GVHR  (3,  5,  6).  In 
GVHD,  K,  I-A,  or  D  differences  induce  about  the  same  degree  of mortality  (3), 
although I-C differences require the preimmunization of donors to cause mortality (5, 
6). The I-B and I-J subregions have not been shown to induce GVHR  (5). Minor H 
loci can induce GVHR  provided donor cells are presensitized and  injected  intrave- 
nously (i.v.) in high doses (7). 
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TABLE  I 
H-2 Haplotype Origin of Strains Used 
Strain  Haplotype  K 
A 
Region* 
I  S  G  D 
B  j  E  C 
BI0.BR  k  k  k  k  k  k  k  k  k  k 
B10.S  s  s  s  s  s  s  s  s  s  s 
B10  b  b  b  h  b  b  b  b  b  b 
A.TH,  B 10.S(7R)  t2  s  s  s  s  s  s  s  s  d 
A.TL  t 1  s  k  k  k  k  k  k  k  d 
B10.HTT  t3  s  s  s  s  k  k  k  k  d 
B10.A(3R)  i3  b  b  b  b  k  k/d  d  d  d 
B 10.A(5R)  i5  b  b  b  k  k  k/d  d  d  d 
B 10.AQR  yi  q  k  k  k  k  d  d  d  d 
B 10.T(6R)  y2  q  q  q  q  q  q  q  q  d 
* Haplotype of origin according to references (44, 45). 
The GVHR represents the first phase in our procedure used to generate a soluble, 
lymphocyte-derived, allogeneic effect factor (AEF)  (8).  An analysis of the activity of 
an  H-2-restricted AEF  has  indicated  that  such  an AEF,  produced  across an  entire 
H-2  region  disparity,  contains  Ia antigens  determined  by the  I-A  subregion  of the 
stimulator  haplotype  (8).  This  AEF  will  help  B  cells  of the  stimulator  but  not 
responder  haplotype,  and  will  only help  B  cells of other strains  which  express  the 
same I-A  determinants as the stimulator cells. This H-2 restriction of the activity of 
AEF  has now been  observed for several AEFs  produced  across  various /-subregion 
differences (9).  However, the mechanism which controls this H-2 restriction phenom- 
enon is not yet understood. 
Recently,  Nagy  et  al.  (10,  11)  have  reported  that  different  subpopulations  of 
responder T-cell blasts can during an MLR absorb either irradiated stimulator cell 
derived  H-2  or  Ia  antigens.  In  an  attempt  to  understand  the  basis  for  the  H-2 
restriction of AEF activity described above, we examined the ability of responder T- 
cell  blasts  to  acquire  H-2  and  Ia  antigens  of the  stimulator  haplotype  during  a 
GVHR. 
In this study, we demonstrate that donor T  cells which  mediate a  GVHR  do not 
express Ia antigens  determined  by the donor haplotype but  do acquire  Ia antigens 
determined  by  the  recipient  haplotype.  In  addition,  we  show  that  injection  of 
recipients  during  the  proliferative phase of the GVHR  with  an antiserum  directed 
against recipient Ia antigens can markedly suppress the GVHR. Based on these data, 
a  model is presented which attempts to explain the role of Ia antigeps in the genetic 
control of allogeneic lymphocyte interactions. 
Materials and Methods 
Mice.  Inbred strains of mice were raised in our mouse colony at University of Toronto. The 
B10.AQR and BI0.T(6R) mice were a  generous gift from Dr.  R. A. Phillips,  Department of 
Medical Biophysics, University of Toronto. The H-2 haplotypes of the strains used in this study 
are listed in Table I. 
Antisera.  The  hyperimmune antisera  used  in  this  study  and  the  respective H-2  regions 
k  k  k  s  immunized against are as follows: A.TH anti-A.TL (anti-/ , S , G  ); A.TL anti-A.TH (anti-/, 
S ", G");  (A.TH  ×  B10.HTT)Fa anti-A.TL (anti-/-A ~, I-B k, I-Jk);  B10.S(7R)  anti-B10.HTT PRUD'HOMME,  SOHN,  AND DELOVITCH  139 
(anti-I-E  ~,  I-C  k,  S k,  Gk);  BI0.A(3R)  anti-B10.A(5R)  (anti-l-Jk);  C3H.SW  anti-C3H/DiSn 
(anti-H-2k); C3H/DiSn anti-C3H.SW (anti-H-2b). The sera were raised by hyperimmunization 
of recipient mice with donor spleen and lymph node lymphocytes as described by Okumura et 
al. (12). The IgG fractions of these antisera were prepared by ammonium sulphate precipitation 
followed by ion-exchange chromatography on QAE Sephadex A-50 (Pharmacia Fine Chemicals 
Div. of Pharmacia Inc., Piscataway, N. J.), they were then dialyzed against phosphate-buffered 
saline  (PBS),  pH  7.2,  aliquoted,  and  stored  at  -70°C  until  use.  Before  use,  these  IgG 
preparations were absorbed with spleen cells of selected strains shown in Tables II and IV. 
F(ab')2 fragments of goat anti-rabbit Fab, F(ab')2 of rabbit anti-mouse Fab, and F(ab')2 of 
rabbit anti-mouse Thy-1 antigen (13) were kindly supplied by Dr. M. Letarte, Department of 
Medical  Biophysics,  University of Toronto.  These  preparations were  conjugated  to  either 
fluorescein isothiocyanate (FITC) or tetramethyl rhodamine isothiocyanate (TRITC)  (British 
Drug Houses Ltd., Poole, England) during dialysis against these fluorochromes. Briefly, samples 
at a concentration of 15-20 mg/ml were dialyzed overnight at 4°C against FITC or TRITC at 
a  concentration of 0.1  mg/ml in 0.05  M  NaHCOa,  pH 9.5.  To remove unbound  FITC and 
TRITC, samples were further dialyzed against 0.01  M  TRIS-HCI, pH 7.6, containing 0.01  M 
NaC1 and 0.01%  Na azide. 
Anti-Ly 1.2 and  anti-Ly 2.2  sera were characterized and  kindly supplied by Dr.  I.  F. C. 
McKenzie, Department of Medicine, Austin Hospital, Heidelburg, Victoria, Australia. 
Complement.  The source of complement was normal rabbit serum that was absorbed with 
EDTA-agarose and then spleen cells and thymocytes. 
Production ofAlloactivated T Cells by GVHR.  Alloactivated T cells were obtained as previously 
described (8).  Briefly,  10  a donor thymocytes from  mice  (4-8 wk old)  were injected i.v. into 
irradiated  (800  rads)  recipients (8-12  wk old)  of matched  sex.  Recipient spleen cells were 
recovered 5 d later (viability as estimated by trypan blue exclusion was 70-80%), and dead cells 
were removed by centrifugation on a  100% heat-inactivated fetal calf serum (FCS) gradient. 
Using immunofluorescence, >95% of live cells recovered were serologicaily found to be T  cells 
which expressed H-2(H-2K and H-2D) antigens of the donor haplotype. 
Treatment of Cells with Anti-Ly and C'.  Optimal conditions of treatment  were determined 
from pilot experiments. Cells were incubated with anti-Ly 1.2  (dilution  1:10)  or anti-Ly 2.2 
(dilution 1:25)  for 30 rain at room temperature. They were then centrifuged and resuspended 
in C' (dilution 1:9) and further incubated for 45 rain at 37°C. The percent lysis achieved with 
these antisera was assessed by trypan blue exclusion. Treatment with anti-Ly 1.2 lysed 35-40% 
of alloactivated cells whereas anti-Ly 2.2 lysed 25-30% of cells above the normal mouse serum 
(NMS) and C' control. 
Immunofluorescence.  Samples containing 2.5  ×  l0  s cells each in PBS-5% FCS were treated for 
15 min at 4°C with 50 #1 of the IgG fractions of either anti-H-2 (2.1 mg/ml) or anti-Ia (1.8 
mg/ml) diluted 1:3 with PBS containing 5% FCS and 0.01%  Na azide, as previously reported 
(14). Cells were then centrifuged through 100% heat-inactivated FCS, washed once, and treated 
with 50/.d of either FITC or TRITC-conjugated F(ab')2 of rabbit anti-mouse Fab (0.4 mg/ml) 
diluted  1:50 with PBS-5% FCS-0.01% Na azide. They were incubated and washed as above 
and  prepared for analysis. Staining for Thy-l.2 positive cells was similarly performed using 
rabbit anti-Thy-1 (14) and TRITC-conjugated F(ab')2 of goat anti-rabbit Fab (0.25  mg/ml). 
Approximately 200  cells  in  each  preparation  were  scored  for  fluorescence  using  a  Leitz 
Orthoplan fluorescence microscope, (Wild Leitz Canada Ltd., Willowdale, Ontario) equipped 
with a Ploemopak 2 illuminator and HBO 50 watt ultra high pressure mercury lamp. 
Suppression Of GVHR with Anti-la Serum.  Irradiated (800 rads) recil~ient B10.AQR mice (age 
• 8-11  wk)  were injected i.v. with 5  ×  107 thymocytes and  5  ×  10' spleen cells from donor 
B10.T(6R) mice (age 6-8 wk) of the same sex. Recipients were divided into four groups (A-D). 
Group A  mice were injected intraperitoneally (i.p.) daily for 7 d  with  100 pl  (diluted 1:2) of 
normal mouse serum  (NMS). The first serum injection was 8  h  before transfer of allogeneic 
cells. Group  B  and  C  mice  received  10  and  100  /11  of A.TH  anti-A.TL  (anti-/k, S k,  Gk), 
respectively, according to the same schedule as group A. A  fourth  group  (D)  received only 
irradiation and  neither allogeneic cells nor antiserum.  Mice were  injected with serum  and 
weighed daily. At day 7 after the transfer of donor cells, all recipient mice were sacrificed and 
the  ratio of spleen weight  to  body  weight  was  determined  for each  mouse  and  expressed 
according to the following spleen weight index (15): 140  HOST ALLOANTIGENS ON  DONOR  CELLS 
TABLE  II 
GVHR Across a  Whole H-2 Complex  Incompatibility  * 
Donor  Recipient  H-2 Incom-  H-2 Regions de- 
patibility  tected by antisera~ 
Percent donor lym- 
phocytes stained 
Specific  Control§ 
B10  B10.BR  H-2  k  K k, D k  40  8 
BI0  B 10.BR  H-2  k  I k, S  k, G k  50  9 
B10  B 10.BR  H-2 k  I  ~, S  s, G ~  4  6 
BI0.S(7R)  B10.BR  H-2  k  K k, D k  33  8 
B 10.S(7R)  B 10.BR  H-2  k  I k, S  k, G k  38  9 
BI0.S(7R)  BI0.BR  H-2  k  V, S", G"  4  9 
B 10.S(7R)  BI0.BR  H-2  k  I-A  k, I-B  k, I-J  k  36  3 
B 10.S(7R)  B10.BR  H-2  k  I-E  k, I-C  k, S  k, G k  2  5 
B10.S(7R)  BI0.BR  H-2  k  I-J  k  4  1 
BI0.BR  (BI0.BR  ×  BI0.S)FI  H-2  ~  I k, S k, G k  5  -- 
BI0.BR  (BI0.BR  ×  BI0.S)F~  H-2  ~  V, S', G  s  30  -- 
(BI0.BR ×  B10.S)FI  B10.BR  None  I k, S  k, G k  8  -- 
(BI0.BR  ×  B10.S)F~  Bt0.BR  None  I  ~, S", G s  5  -- 
* See text for explanation. 
Anti-K k, D k was produced by extensive absorption of C3H.SW anti-C3H/DiSn (anti-H-2  k) with A.TL 
k  k  spleen  cells as determined by the dye exclusion  mierocytotoxicity assay  (16). Before use, anti-K , D  ; 
anti-l-A k, I_B k, l_jk; anti_lh, S k, Gk; anti_l_E k, I_C k, S k, G k  and anti-l-J  '~ were absorbed with donor B 10, 
B10.S(TK),  and B10.T(6R)  spleen cells. Anti-P, S ~, G ~ was absorbed  with A.TL, BI0, and BI0.T(6R) 
spleen  cells. Absorptions  were performed by incubating  150 #1 of serum twice with 5  ×  10 7 cells of a 
given strain for 30 min at 4°C. Sera were spun  at  100,000 g for  1 h immediately before use to remove 
possible aggregates. 
§ Donor cells were injected into B10.T(6R)  recipients. 
spleen weight in grams 
body weight in grams 
×  1,000. 
A statistical analysis was carried out using the Student's t test. 
Results 
GVHR  across Entire  H-2-Region  Differences.  Various  strain  combinations  were used 
to  activate  donor  cells  during  a  GVHR  against  H-2-associated  alloantigens  of the 
recipient.  It  was  of interest  to  determine  whether  alloactivated  donor  T  cells  can 
acquire,  in  vivo,  H-2  and  Ia  antigens  from  the  surface  of recipient  cells.  This  was 
examined  by  the  immunofluorescent  staining  of these  donor  cells with  alloantisera 
(rendered  specific  by  absorption)  directed  against  the  recipient  H-2  haplotype. 
Representative  results  are  shown  in  Table  II.  Control  values  were  obtained  by  the 
injection of donor cells into B10.T(6R)  hosts,  which carry an H-2 haplotype different 
from  that  of the  specific  recipient  haplotype.  With  the  B10(H-2b):  B10.BR(H-2 k) 
donor;  recipient  combination,  40%  of the  cells  recovered  from  the  recipient  spleen 
(>95%  donor  haplotype  when  stained  with  C3H/DiSn  anti-C3H.SW  [anti-H-2b]) 
stained with the anti-K  k, D k antiserum.  An example of such a  stained cell is shown in 
Fig.  1. Approximately  50% of the recovered cells were stained with anti-/k, S k, G k. By 
contrast,  control  samples  yielded  <10%  staining.  Another  combination  which  em- 
ployed B 10.S(7R)  donor cells and  B 10.BR recipient cells demonstrated  that  -~33% of 
donor  cells were stained  with  anti-K  k,  D ~,  whereas  38%  and  36%  of these  cells were 
stained with anti-/k, S k, G k, and anti-/-A  k, I-B k, I-J k, respectively. No positive staining FIo.  1.  lmmunofluorescence of a  donor blast T  cell. The photo on the top (A)  shows donor blast 
T  cells stained with F(ab')~ fragments of rabbit anti-mouse Thy-1 and TRITC-conjugated F(ab')2 
fragments of goat anti-rabbit Fab. The photo on the bottom (B) shows a  donor blast T  cell stained 
with anti-recipient anti-la serum and FITC-conjugated F(ab')2 fragments of rabbit anti-mouse Fab. 
Magnification, 400  ×. 
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TAaLE  III 
Anti-Ly Plus C' Treatment of Donor Cells  * 
Donor  Recipient  H-2 Incompati-  Anti-Ly +  C'  H-2 regions de-  Percent  lym-  tected by anti-  phocytes 
bility  treatment  sera:~  stained 
BI0  BI0.BR  H-2  k  Anti-Ly 1.2  K k, D k  68 
B10  B10.BR  H-2  k  Anti-Ly t.2  I  k, S  k, G  k  I5 
BI0  BI0.BR  H-2  k  Anti-Ly 2.2  K k, D  k  l 1 
B10  B 10.BR  H-2  k  Anti-Ly 2.2  I  k, S  k, G  k  69 
B10  BI0.BR  H-2  k  --  K k, D k  40 
B10  B 10.BR  H-2  k  --  I k, S k, G k  50 
* See text for explanation. 
:]: Sera were absorbed as described in the legend to Table II. 
of these  donor cells  above the control  values  (<10%)  was observed upon  treatment 
with either anti-I-J k or anti-I-E  k, I-C x, S x, G x. With the B10.BR-donor and (BI0.BR 
X  B10.S)Frrecipient  combination,  30% of donor cells were stained  with anti-/8,  S 8, 
G *, although only 5% of these cells were stained with anti-I  x, S x, G x. 
In each of the above combinations, the stimulation  of a  GVHR  across an incom- 
patibility  in the whole Ho2 complex generated  donor ceils recovered  from recipient 
spleens that were comprised of m50-60% large T  cells or blasts (a blast was considered 
to have two  ×  diameter of a small lymphocyte (11)). Approximately 70-80% of donor 
cells  that  were  stained  with  alloantisera  against  the  recipient  H-2  haplotype  were 
identified as T-cell blasts. However, no attempt was made here to distinguish between 
large  and  mid-size  blasts  and  small  lymphocytes  since  we  found  this  introduced 
inconsistency  in  counting.  For  this  reason,  all  stained  cells  were  counted  in  each 
preparation.  In addition,  >95%  of these  lymphocytes were  found  to express  donor 
haplotype controlled H-2 but not Ia antigens,  i.e., these cells were predominantly of 
donor origin. 
The results presented here suggest that recipient-derived H-2K and H-2D antigens 
and  Ia  antigens  controlled  only  by  the  I-A  subregion  (no  known  Ia  antigenic 
specificities  are  controlled  by  I-B),  may  be  absorbed  onto  the  surface  of donor- 
alloactivated  T  cells. The lack of staining observed with anti-l-J  x may be due to its 
relatively  low  cytotoxic  activity  (<10%  lysis  of  B10.BR  target  cells).  The  same 
explanation cannot be attributed  to the absence of staining seen with anti-I-E  x, I-C x, 
S x,  G x, which  lyses 50-60%  of BI0.BR lymph  node cells  with  a  titer  of 1:640 in  a 
microcytotoxicity assay (16). 
Effect of Treating  GVHR Donor Cells with Anti-Ly Sera and C'.  Nagy et al.  (11)  have 
found that MLR responder T  cells of the Lyt-1 +, 2-, 3- phenotype adsorb Ia antigens 
of the stimulator haplotype, whereas responder T  cells of the Lyt-1-, 2 +, 3 + phenotype 
adsorb H-2K and H-2D antigens of the stimulator  haplotype. The following experi- 
ment  was performed  to determine  whether similar subpopulations  of GVHR  donor 
T  cells acquire host H-2 and Ia antigens. Treatment  with anti-Lyt-1.2 and C' of B 10 
donor cells activated in B10.BR recipients resulted in an increase in the percentage of 
cells stained with anti-K  x, D k from 40 to 68% and a decrease in cells stained with anti- 
I x, S x, G x from 50 to 15% (see Table III). On the other hand, treatment with anti-Lyt- 
2.2 and C' increased the percent cells stained with anti-/x, S x, G x from 50 to 69% but 
decreased the percent of cells stained with anti-K  x, D k from 40 to  11%. These results PRUD'HOMME,  SOHN,  AND  DELOVITCH 
TABLE  IV 
G VHR Across an I-Region or I-Subregion Incompatibility* 
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Donor  Recipient  H-2 Incompatibil-  H-2 regions de- 
ity  tected by antisera.']: 
Percent donor lym- 
phocytes stained 
Specific  Control§ 
A.TH  A.TL  I k, S k, G k  I k, S k, G k  37  3 
A.TH  A.TL  I k, S k, G k  I', S', G"  2  30 
A.TH  A.TL  I k, S k, G k  I-A  k, I-B  k, l-J  k  36  7 
A.TH  A.TL  I k, S k, G k  LE  t , I-C  k, S k, G t  2  6 
(A.TH  ×  BI0.HTT)F1  A.TL  I-A  k, I-B  t, I-Jit  lit, Sit, Git  34  6 
(A.TH  ×  B10.HTT)F~  A.TL  I-Ait, I-Bit, I-J  t  I', S', G"  9  33 
(A.TH  ×  B10.HTT)F1  A.TL  l-Ait, I-Bit, l-J  t  I-Ait, I-B  It, I-Jit  32  6 
(A.TH  ×  B 10.HTT)F~  A.TL  I-A  t, I-B  k, I-Jit  I-E  t, I-C  t, S t, G k  5  5 
(A.TH  ×  BI0.HTT)F~  A.TL  I-A  k, I-B  t, I-J  k  I-J  t  4  6 
B 10.S(7R)  B 10.HTT  I-E  t, I-C  t, S t, G k  I a, Sit, G t  16  3 
BI0.S(7R)  BI0.HTT  LE t, I-Cit, Sit, G t  I', S', G'  7  7 
B 10.S(7R')  BI0.HTT  I-E  t, I-Cit, S t, G k  I-Eit, I-Ca, Sit, Git  7  6 
B 10.S(7R)  B 10.HTT  I-Eit, I-C  k, S t, Git  bE t, I-C  t, Sit, Git  3  7 
B10.A(3R)  B10.A(5R)  I-J  k  lit, S k, Git  8  8 
B10.A(3R)  BI0.A(5R)  l-Jit  l-J  k  7  6 
* See text for explanation. 
Absorption of anti-I k, S k, G*; anti-l-A k, I-B k, l-Jk; anti-l-E k, I-C k, S k, G*; and anti-l-j* were performed 
with A.TH and  BI0.S(7R)  spleen cells. Anti-/~, S s, G ~ was absorbed  with A.TL and  BI0 spleen cells. 
Absorptions were performed as described in the legend to Table I[. 
§ Controls consisted of reciprocal combinations, i.e., recipient and donor strains were interchanged. 
parallel those previously obtained with MLR-responder T  cells mentioned above and 
are consistent with a similar Ly phenotype and function for GVHR-activated donor 
T  cells. 
GVHR across I-Region and I-Subregion Differences.  Donor cells were treated with anti- 
Ia  antisera  directed against  different 1-subregions of the  recipient haplotype in  an 
attempt to map the la  loci coding for the Ia antigens which become adsorbed onto 
the donor T  cells.  Typical results are presented in  Table IV.  Control values were 
obtained with the reciprocal combinations of those used in the test combinations, i.e., 
recipient  and  donor  strains  were  interchanged.  In  the  A.TH-A.TL  combination, 
which  leads  to an  activation  across  the  /~  region,  37%  of A.TH  donor cells were 
stained with anti-/k, S ~, G k and 36% of the cells were stained with anti-/-A k, I-B k, I-J k. 
No positive staining was observed with either anti-/-E  k, I-C k, S k, G k, or anti-I  ", S s, G s. 
In the reciprocal combination, 30% of A.TL donor cells were stained with anti-P, S ~, 
G ~, although anti-I  s, S k, G k yielded background level staining. Similar results to those 
described above were obtained by activation across the I-A k, I-B  ~, and I-J k subregions 
in the (A.TH  ×  B10.HTT)Fa-donor and A.TL-recipient combination. 
By contrast, activation across either I-E k, I-C k, S k, and G k (B 10.S[7R]--donor and 
B10.HTT--recipient) or across I-J k  (B10.A[3R]--donor and  B10.A[5R]--recipient) 
yielded a background level of staining with all antisera used. 
All  combinations  which  involved an  I-A  subregion  incompatibility  gave  rise  to 
donor cells composed of 40-50% blast cells. These blasts represented m70-80% of the 
positively stained  cells.  However, activation  across  either I-J  or I-E,  I-C,  S,  and  G 
differences yielded <5% blasts.  Positive results therefore correlated closely with the 
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FI~.  2.  Suppression of the GVHR with anti-host anti-Ia  serum. Groups A, B, and C represent 
B 10.AQR irradiated mice that received an i.v. injection of B 10.T(6R) spleen cells and thymocytes. 
Group D mice received only irradiation. Beginning on the day of allogeneic cell transfer, group A 
mice received 100 ~,1 of NMS i.p. daily and groups B and C received 10 #1 and  100 ~1 of anti-Ia k 
serum, respectively. At day 7, all  mice were sacrificed and  the spleen to body weight ratio was 
determined for each mouse. Numbers in parentheses represent the number of mice used per group. 
Suppression of GVHR  by Injection of Anti-Ia  Serum  to Host Antigens.  Previous reports 
demonstrated  both  in  clinical  studies  (17)  and  animal  model  systems  (18-22)  that 
anti-recipient  antibodies  can  suppress  the  GVHR.  However,  the  reactivity  of these 
sera  versus  specific  MHC  products  was  not  shown.  The  following experiment  was 
therefore  performed  to  determine  if an  anti-Ia  antiserum  to  recipient  Ia  antigens 
could suppress the GVHR. The combination used here consisted of B 10,T(6R) donors 
and B10.AQR recipients, which results in the activation across the/-A k, I-B k, I-J k, I- 
E k, I-C k, S a, and G a regions. Recipient mice were administered daily i.p. injections of 
either anti-/k, S k, G k, or A.TH NMS. Their spleen weight indices were evaluated  7 d 
after irradiation and cell transfer. As can be seen from Fig. 2, mice undergoing GVHR 
that  received  100 #1  of NMS  (group A)  had  a  marked  splenic  enlargement  (spleen 
weight  index  =  7.64).  Group  B  mice,  which  received  10 #1  of anti-/k,  S k,  G k,  had 
significantly smaller spleens  (spleen weight index  =  5.56; B <  A, P <  0.001). Group 
C  mice which received  100 #1 of anti-/k,  S k, G k had the smallest  spleens of the three 
groups (spleen weight index  =  4.14; C  <  B <  A, P <  0.001) as they possessed average 
spleen  weights  almost  one-half that  of group A.  The  control  Group  D  mice which 
received  only  irradiation  and  no  allogeneic  cells  had  still  smaller  spleens  (spleen 
weight index  =  1.15). 
These data indicate that the administration  of recipients with alloantisera directed 
against their Ia antigens can markedly suppress an ongoing GVHR  response. Whether 
this suppression occurs via the interaction ofanti-Ia with either the irradiated recipient 
cells or the transferred donor cells which have absorbed recipient Ia antigens, or both 
of these cell populations, remains to be determined. 
Discussion 
Data presented here establish a definite parallelism  between the functional activity 
of alloactivated  T  cells  responsive  in  vitro during  an  MLR  and  those  responsive  in 
vivo during a GVHR. Nagy et al.  (10,  11) previously reported that different subpop- 
ulations of MLR  responder T-cell blasts acquire either K- and D-region products or 
/-region  products  from the  irradiated  stimulator  cells.  However,  these  investigators 
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appear on  the surface of the responder T  cells.  In  this study, we have shown  that 
GVHR donor cells can absorb K-, D- and/-region products from irradiated recipient 
cells.  Furthermore, we  have  demonstrated  that  only host  cell  products of the  1-A 
and/or  1-B  subregion  (presumably  only  the  1-A  subregion  is  involved  here)  are 
identifiable on donor ceils. These results are consistent with the finding that an 1-A 
subregion difference leads to a strong stimulation of the GVHR (3, 5, 6), whereas an 
I-C subregion  difference causes  only a  relatively weak stimulation  that  requires a 
presensitization of the donor cells (5, 6).  I-B and  I-J differences do not stimulate a 
GVHR response (5). Whether recipient H-2 and Ia antigens bind to activated donor 
cells either directly to their surface or indirectly via the interaction with specific cell 
surface receptors remains  to be determined.  In  each instance, this  type of binding 
must  occur in such a  manner that  the allodeterminants of these molecules must  be 
exposed for reactivity with their respective antibodies. 
The uptake by donor cells of host MHC gene products may also have an important 
physiological role in  immune  surveillance and  protection. Such  an  hypothesis has 
been suggested  to explain  the  protection of lung Schistosoma mansoni schistosomula 
from immune destruction resulting from the binding to these organisms of the infected 
allogeneic recipient H-2 antigens (23). It is possible that such a mechanism may also 
immunologically protect fetal cells in the maternal circulation by the acquisition of 
paternal MHC gene products by the maternal cells. 
Cantor  and  Boyse  (24,  25)  have determined  the  Ly phenotype of two different 
lymphocyte subpopulations functional in an MLR. They have reported that Ly-1  +, 
2-, 3- responder T  cells recognize Ia antigens, whereas Ly- 1-, 2 +, 3  + responder T  cells 
recognize H-2K and H-2D antigens. Nagy et al.  (11) found that MLR-stimulator cell 
Ia antigens  bind  to Ly-1 ÷,  2-,  3- responder T  cells, whereas H-2K antigens of the 
stimulator  cell  bind  to  Ly-l-,  2  ÷,  3  +  responder  T  cells.  Our  studies  on  GVHR 
activated  donor  cells  have  corroborated  these  MLR  data.  We  have  shown  that 
treatment of GVHR alloactivated donor T  cells with anti-Ly-1.2 and C' significantly 
reduced  the  percentage of the  surviving  viable cells stained  with  antisera  against 
recipient Ia antigens but increased considerably the percentage of cells stained with 
an antiserum against recipient H-2K and H-2D antigens. Treatment of the activated 
donor cells with anti-Ly-2.2 and C' yielded the opposite result. It should also be noted 
that Eshhar et al. (26)  found that pretreatment with anti-Ly-l.2 plus C' of the MLR 
responder cells used to produce an AEF resulted in their inability to obtain any T-cell 
replacing activity with such an AEF. It therefore appears that the Ly phenotype of 
donor T  cells responsive during a GVHR is the same as that of the responder T  cells 
in an MLR. 
The results obtained in this study serve to further delineate the role of Ia antigens 
in the GVHR response. The daily injection of irradiated recipients with an antiserum 
against self Ia antigens produced a marked suppression of the resulting GVHR. The 
degree of suppression observed was dependent on the dose of anti-Ia administered. It 
should  be  mentioned  that  no  attempt  was  made  here to  determine  the  optimum 
kinetics and dose of administration of anti-Ia antisera. In addition, it is not yet known 
whether this type of suppression can occur via the binding of such an anti-Ia antibody 
either to the surface of the transferred donor cells which have absorbed recipient Ia 
antigens or directly to the surface of the irradiated recipient cells, or perhaps to both 
of these cell populations. Anti-Ia antisera reactive with 1-J determinants may eliminate 
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eliminate helper T-cell function in vivo (28). Because recipient Ia antigens determined 
by the 1-A subregion appear to be absorbed to GVHR activated donor, Ly-1  ÷, 2-, 3- 
T  cells, it is  possible that  the anti-Ia antiserum  used here, which contains anti-I-A 
activity, suppressed the GVHR in part by binding to and abrogating the function of 
this subpopulation of donor T cells. Conversely, it is also likely that a GVHR response 
may be suppressed by the reaction of anti-recipient Ia antibodies with recipient cells. 
This suggestion is based on the observations that  (a)  MLR  (29-33)  and CML  (34) 
responses may be inhibited by anti-Ia antisera directed against the MLR stimulator 
and CML target cells, respectively, and (b) skin (35),  z heart,  2 and kidney (36) allograft 
survival may be enhanced by treatment of transplant recipients with anti-donor anti- 
Ia antisera. 
Anti-recipient  alloantibodies  have  previously  been  used  to  suppress  a  GVHR 
response (6,  18-22), but only one such report documented the use of an anti-Ia serum 
(6).  In  this  instance,  however, a  single injection of anti-recipient Ia antibodies was 
given on day 0 to donors and not to recipients. It was found that if these donor cells 
were  recovered within  8-14  d  after serum  pretreatment,  they  produced  a  weaker 
GVHR when subsequently injected into newborn mice. Only the donor spleen cells, 
but not the donor lymph node cells, were suppressed. The use of antisera to either I- 
A or I-C determinants resulted in an equivalent amount of suppression. The mecha- 
nism  for this type of suppression  is not clear in  view of the relatively low doses of 
antisera injected, the similar degree of suppression obtained with anti-I-A and anti-l- 
C, and the short duration of the induced suppression. 
The ability  (a)  to detect recipient  Ia antigens on activated donor cells during a 
GVHR  response  and  (b)  to suppress  such  an  alloactivation  with  anti-recipient  Ia 
antibodies may provide further insight into the mechanism(s) of allogeneic lymphocyte 
interactions. A central role for Ia antigens in the regulation of lymphocyte interaction 
during an immune response has been suggested (reviewed in references 38-40). Based 
on our studies with AEF, we have proposed that Ia antigens represent a second signal 
(immunizing antigen represents the first signal) required for the activation of a B cell 
to antibody production (8, 9). The capacity of GVHR and MLR alloactivated T  cells 
to acquire stimulator cell Ia antigens on their surface may explain why the helper 
activity  of an  Ia-positive  AEF  generated  across  various  /-subregion  differences is 
restricted to B cells of the stimulator haplotype (9).  AEF preparations which consist 
of Ia antigens determined only by the stimulator haplotype provide little or no help 
for B cells of the responder haplotype (8).  This H-2 restriction of AEF activity may 
therefore be controlled by the recognition and like-like interaction between AEF Ia 
antigens,  which  are  initially  stimulator  cell  derived  and  are  then  adsorbed  onto 
allogeneic responder T  cells, and syngeneic Ia antigens on the B cell. Alternatively, 
AEF Ia antigens may recognize and bind to complementary anti-Ia receptors on the 
B cell. It is also possible that after antigenic stimulation, T  cells may similarly acquire 
B-cell surface derived Ia antigens. In this way, T  cells may recruit and cooperate with 
the  appropriate  syngeneic  macrophages  and  B  ceils  to  activate  these  B  cells  to 
antibody synthesis. 
Ia antigens may also serve as a second signal in an MLR and GVHR response. For 
example, Ia antigens may act as both the stimulating antigen and the second signal 
2 B. Zimmerman et al. 1979. Immunosuppressive  ALS. II. Antibody  to Ia antigens in heterologous  anti- 
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required for either MLR responder T  cell or GVHR donor T-cell activation.  In the 
absence of transfer of Ia antigens  from stimulator  to responder cells  alloactivation 
may  not  occur.  This  view  is  consistent  with  the  finding  that  K-  and  D-region 
differences  alone  stimulate  a  weak  MLR  (42)  and  a  weak  GVHR  (3).  It  is  also 
compatible  with  the  finding  that  the  removal  of K-  and  D-region  reactivity  by 
absorption with erythrocytes from allograft enhancing anti-H-2 sera does not reduce 
their enhancing activity (36, 37). In addition, the recent data of Batchelor et al. (42) 
show that H-2 and Ia antigens are poor immunogens unless presented on viable cells. 
Presumably, metabolically active cells are needed to relay a secondary signal.  2 Anti- 
Ia antibodies to stimulator alloantigens may then suppress alloactivation by interfer- 
ing with the transfer of Ia antigens from stimulator to responder lymphocytes. 
Although  precise mechanisms of action remain uncertain,  it is becoming increas- 
ingly evident that the in vivo injection of anti-Ia antibodies may provide a  powerful 
research and clinical tool for immunomanipulation. In the clinical situation, antisera 
to HLA D-region antigens  (the human analogue of murine Ia antigens)  may prove 
valuable  for  the  prevention  or  treatment  of GVHD  in  bone  marrow  transplant 
recipients. 
Summary 
By  using  an  indirect  immunofluorescence  technique,  the  presence  of  host  cell 
derived  Ho2K,  H-2D,  and  Ia  alloantigens  on  donor  cells  recovered  from  recipient 
spleens after a graft-versus-host response (GVHR) was demonstrated. Mapping studies 
indicated that only host K, D, and I-A region gene products could be identified on the 
donor cells. Host I-E/C- and/-,]-subregion products were not absorbed by donor cells. 
Treatment of activated donor cells with anti-Ly sera plus C' revealed that donor cells 
carrying host Ia antigens have a Ly-1  +, 2-, 3- phenotype, whereas donor cells carrying 
H-2K and H-2D host antigens have a  Ly- 1-, 2 ÷, 3 + phenotype. 
A  GVHR  that  resulted  from only an/-region  incompatibility was suppressed by 
the  injection  of recipient  mice  with  an  anti-Ia  antiserum  directed  against  self Ia 
antigens.  The  degree  of  suppression  was  proportional  to  the  amount  of  anti-Ia 
antiserum administered. 
We thank Ms. Minnie Taishi for her expert secretarial assistance. 
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